Literature DB >> 23178638

Comparison of surveillance strategies for low-risk bladder cancer patients.

Yuan Zhang1, Brian T Denton2, Matthew E Nielsen3.   

Abstract

OBJECTIVE: Low-grade noninvasive disease comprises approximately half of incident bladder cancer cases. These lesions have exceedingly low rates of progression to aggressive, muscle-invasive bladder cancer, and there is salient discordance with regard to management recommendations for these patients between the principal clinical practice guidelines. In this context, we compare the international guidelines with alternative surveillance strategies for low-risk bladder cancer patients.
METHODS: We used a partially observable Markov model based on states that defined patient risk levels associated with recurrence and progression of bladder cancer. The model also included states defining the effects of treatment, death from bladder cancer, and all other-cause mortality. Simulation was done to estimate quality-adjusted life years (QALYs), expected lifelong progression probability, and lifetime number of cystoscopies.
RESULTS: We compared current international guidelines and additional proposed surveillance strategies on the basis of QALYs. We conducted a bicriteria analysis to compare expected lifelong progression rate v. the number of cystoscopies. One-way sensitivity analysis was used to evaluate the influence of model parameters, including a patient's disutility associated with cystoscopy, bladder cancer mortality, and all other-cause mortality.
CONCLUSIONS: Age and comorbidity significantly affect the optimal surveillance strategy. Results suggest that younger patients should be screened more intensively than older patients, and patients having comorbidity should be screened less intensively.

Entities:  

Mesh:

Year:  2012        PMID: 23178638     DOI: 10.1177/0272989X12465353

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model.

Authors:  Zongren Wang; Han Xiao; Guangyan Wei; Ning Zhang; Mengchao Wei; Zebin Chen; Zhenwei Peng; Sui Peng; Shaopeng Qiu; Heping Li; Jianting Long
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

2.  Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Authors:  Eveline A M Heijnsdijk; Daan Nieboer; Tullika Garg; Iris Lansdorp-Vogelaar; Harry J de Koning; Matthew E Nielsen
Journal:  BJU Int       Date:  2018-08-27       Impact factor: 5.588

3.  Estimating the Prevalence of Bladder Cancer by Stage in Iran as a Developing Country.

Authors:  Hamideh Rashidian; Ali Akbar Haghdoost; Rajabali Daroudi; Mehdi Raadabadi; Mohammad Reza Ebadzadeh; Kazem Zendehdel
Journal:  Med J Islam Repub Iran       Date:  2022-04-18

4.  Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma.

Authors:  Olivier Cussenot; Karim Sighar; Mansoor Mohammed; Sylvain Hugonin; Valérie Ondet; Stéphane Larre; Roger Lacave; Morgan Roupret; Géraldine Cancel-Tassin
Journal:  World J Urol       Date:  2013-11-07       Impact factor: 4.226

5.  Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial.

Authors:  Edward Cox; Pedro Saramago; John Kelly; Nuria Porta; Emma Hall; Wei Shen Tan; Mark Sculpher; Marta Soares
Journal:  Clin Genitourin Cancer       Date:  2019-12-14       Impact factor: 2.872

6.  Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices.

Authors:  Beth Russell; Pinky Kotecha; Ramesh Thurairaja; Rajesh Nair; Sachin Malde; Pardeep Kumar; Muhammad Shamim Khan
Journal:  Transl Androl Urol       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.